In gastric cancer, DDX21 has been shown to drive cancer cell proliferation, primarily through the activation of the cyclin D1 and CDK2 signaling pathways, suggesting that DDX21 could serve as a therapeutic target for gastric cancer [57]. Here, CDK2 is linked to gastric cancer.